Efficient Fas-ligand gene expression in rodent liver after intravenous injection of a recombinant adenovirus by the use of a Cre-mediated switching system

Gene Therapy

Volumn 5, Issue 8, 1998, Pages 1047-1053

  Okuyama, T ^a   Fujino, M ^b   Li, X K ^b   Funeshima, N ^b   Kosuga, M ^a   Saito, I ^c   Suzuki, S ^b   Yamada, M ^a  

^a NATIONAL RESEARCH INSTITUTE FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

Cre mediated recombination; Fas mediated apoptosis; Recombinant adenovirus

Indexed keywords

DNA FRAGMENT; FAS LIGAND; RECOMBINASE;

ADENOVIRUS; ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CLONING VECTOR; CONTROLLED STUDY; COSMID; DNA FLANKING REGION; GENE DOSAGE; GENE EXPRESSION; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA CELL LINE; LIVER; NONHUMAN; PLAQUE FORMING CELL; PRIORITY JOURNAL; PROMOTER REGION; RAT; RODENT; VIRUS RECOMBINANT;

ADENOVIRIDAE; ANIMALIA; RODENTIA;

EID: 0031666610     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300704     Document Type: Article

References (27)

1. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993; 75: 1169-1178.
2. Kondo T et al. Essential roles of the Fas ligand in the development of hepatitis. Nature Med 1997; 3: 409-413.
3. Griffith TS et al. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995; 270: 1189-1192.
4. Bellgrau D et al. A role for CD95 ligand in preventing graft rejection. Nature 1995; 377: 630-632.
5. Stuart PM, et al. CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival. J Clin Invest 1997; 99: 396-402.
6. Arai H, Chan SY, Bishop DK, Nabel GJ. Inhibition of the alloantibody response by CD95 ligand. Nature Med 1997; 3: 843-848.
7. Miyazaki J et al. Expression vector system based on the chicken beta-actin promoter directs efficient production of interleukin5. Gene 1989; 79: 269-277.
8. Sternberg N, Hamilton D, Hoess R. Bacteriophage P1 site-specific recombination. II. Recombination between loxP and the bacterial chromosome. J Mol Biol 1981; 150: 487-507.
9. Kanegae Y et al. Efficient gene activation in mammalian cells by using recombinant adenovirus expressing site-specific Cre recombinase. Nucleic Acids Res 1995; 23: 3816-3821.
10. Ogasawara J et al. Lethal effect of the anti-Fas antibody in mice. Nature 1993; 364: 806-809.
11. Kang SM et al. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nature Med 1997; 3: 738-743.
12. Arai H, Gordon D, Nabel EG, Nabel GJ. Gene transfer of Fas ligand induces tumor regression in vino. Proc Natl Acad Sci USA 1997; 94: 13862-13867.
13. Muruve DA et al. Adenovirus-mediated expression of Fas ligand induces hepatic apoptosis after Systemic administration and apoptosis of ex vivo-infected pancreatic islet allografts and isografts. Hum Gene Ther 1997; 8: 955-963.
14. Zhang H et al. Amelioration of collagen-induced arthritis by CD95 (Apo-l/Fas)-Iigand gene transfer. J Clin Invest 1997; 100: 1951-1957.
15. Vrancken Peeters MJ, Perkins AL, Kay MA. Method for multiple portal vein infusions in mice: quantitation of adenovirusmediated hepatic gene transfer. Biotechniques 1996; 20: 278-285.
16. Denning C, Pitts JD. Bystander effects of different enzyme-prodrug systems for cancer gene therapy depend on different pathways for intercellular transfer of toxic metabolites, a factor that will govern clinical choice of appropriate regimes. Hum Gene Ther 1997; 8: 1825-1835.
17. Smiley WR et al. Establishment of parameters for optimal transduction efficiency and antitumor effects with purified high-titer HSV-TK retroviral vector in established solid tumors. Hum Gene Ther 1997; 8: 965-977.
18. Kanai F et al. In vivo gene therapy for α-fetoprotein-producing hepatocellular carcinoma by adenovirus-mediated transfer of cytosine deaminase gene. Cancer Res 1997; 57: 461-465.
19. Strand S et al. Lymphocyte apoptosis induced by CD95 (APO1/Fas) ligand-expressing tumor cells - a mechanism of immune evasion? Nature Med 1996; 2: 1361-1366.
20. Seino K, Kayagaki N, Okumura K, Yagita H. Antitumor effect of locally produced CD95 ligand. Nature Med 1997; 3: 165-170.
21. Rensing-Ehl A et al. A Local Fas/APO-1 (CD95) ligand-mediated tumor cell killing in vivo. Eur J Immunol 1995; 25: 2253-2258.
22. Lacronique V et al. Bcl-2 protects from lethal hepatic apoptosis induced by an anti-Fas antibody in mice. Nature Med 1996; 2: 80-86.
23. Kunstle G et al. ICE-protease inhibitors block murine liver injury and apoptosis caused by CD95 or by TNF-α. Immunol Lett 1997; 55: 5-10.
24. Lau HT, Yu M, Fontana A, Stoeckert CJ Jr. Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science 1996; 273: 109-112.
25. X-K Li et al. Prolonged survival of recipient rats with Fas-ligand transfected liver allografts by using HVJ-liposome. Transplant Proc (in press).
26. Seino K et al. Transplantation of CD95 ligand-expressing grafts: influence of transplantation site and difficulty in protecting allo and xenografts. Transplantation 1997; 64: 1050-1054.
27. Miyake S et al. Efficient generation of recombinant adenoviruses using adenovirus DNA-terminal protein complex and a cosmid bearing the full-length virus genome. Proc Natl Acad Sci USA 1996; 93: 1320-1324.